Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Akorn, Inc.    AKRXQ

AKORN, INC.

(AKRXQ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Fresenius picks up M&A pace with Akorn, Merck KGaA deals

share with twitter share with LinkedIn share with facebook
04/25/2017 | 05:17am EDT
A Fresenius SE logo is pictured in Bad Homburg near Frankfurt

FRANKFURT (Reuters) - German healthcare group Fresenius SE & Co KGaA (>> Fresenius SE & Co KGaA) has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc (>> Akorn, Inc.) for $4.75 billion (£3.72 billion) and the biosimilars arm of Germany's Merck KGaA.

FRANKFURT (Reuters) - German healthcare group Fresenius SE & Co KGaA (>> Fresenius SE & Co KGaA) has stepped up its dealmaking, agreeing to buy U.S. generic drugmaker Akorn Inc (>> Akorn, Inc.) for $4.75 billion (£3.72 billion) and the biosimilars arm of Germany's Merck KGaA.

Takeovers were part of Fresenius's growth strategy under previous boss Ulf Mark Schneider, now leading Nestle (>> Nestle SA). But his successor, former finance chief Stephan Sturm, is lifting the pace, having already bought a Spanish hospital chain for 5.8 billion euros (£4.92 billion) since taking over in June.

The latest deals are in keeping with Fresenius's focus on drugs that have lost patent protection, but also mark a foray into new dosage forms, therapeutic areas and biotech drugs for its Kabi unit, a maker of generic infusion drugs as well as tube feeding and blood transfusion equipment.

Akorn will add products such as medical creams, ophthalmic drugs, oral liquids, ear drops, nasal sprays and respiratory drugs, where competition is relatively benign compared with standard pills and tablets.

"We are putting Fresenius Kabi on track for an even more broadly based and strong sustainable growth beyond the current decade," said Sturm.

The separate deal with Merck KGaA <MRKG.DE> marks an entry into "biosimilar" copies of complex biologic drugs made from living cells, which Fresenius has previously shunned.

"We've always said the regulatory environment would have to clear up before we invest in biosimilars. A lot has been done in that area in the recent past," Sturm added.

Reuters earlier on Monday reported Fresenius was close to acquiring Akorn.

In a deal that has the backing of Akorn's management and its largest shareholder, Fresenius will pay $34 per share and take on Akorn's net debt of about $450 million for a total price tag of $4.75 billion, Fresenius said late on Monday.

It will be financed by a broad mix of euro- and dollar-denominated debt instruments.

Berenberg analyst Tom Jones said the price tag of 12.4 times Akorn's core earnings (adjusted EBITDA) estimate for 2017 should not "give anyone any great cause for concern".

He flagged some risks related to Akorn's older drugs that might draw scrutiny from U.S. healthcare regulators but was reassured by the buyer's "long history of doing M&A, and doing it relatively well".

Fresenius shares were up 0.9 percent at 0750 GMT, broadly in line with the European healthcare index <.SXDP>.

For the Merck deal, Fresenius will pay an initial 170 million euros and up to 500 million in milestone payments tied to the achievement of drug development targets as none of Merck's biosimilar drugs have been launched yet.

Merck also stands to receive single-digit percentage royalties on sales.

Fresenius said it expected first revenues towards the end of 2019. It also said it was prepared to spend and invest up to 1.4 billion euros to build up the new business through 2022, including the upfront and milestone payments to Merck.

Fresenius, with a market capitalisation of more than 40 billion euros, runs businesses ranging from kidney dialysis and drug manufacturing to hospital management.

Group net debt as a multiple of core earnings will temporarily increase to about 3.3 after both transactions but is expected to return to about 3 at the end of 2018.

Fresenius has for years enjoyed low borrowing costs because of its diversified businesses in an industry largely immune to swings in the business cycle.

The buyer's main advisers on the Akorn deal were investment banks Credit Suisse (>> Credit Suisse Group AG) and Moelis (>> Moelis & Co), as well as law firm Allen & Overy.

(Reporting by Ludwig Burger; Editing by Grant McCool and Mark Potter)

By Ludwig Burger


Stocks mentioned in the article
ChangeLast1st jan.
AKORN, INC. 0.65% 0.027 End-of-day quote.-98.20%
CREDIT SUISSE GROUP AG -4.23% 9.108 Delayed Quote.-27.87%
E.ON SE -4.04% 8.96 Delayed Quote.-5.84%
FORBO HOLDING AG -2.00% 1378 Delayed Quote.-15.05%
FRESENIUS SE & CO. KGAA -4.13% 32.37 Delayed Quote.-36.19%
MERCK KGAA -0.81% 134.75 Delayed Quote.27.29%
MOELIS & COMPANY -5.79% 37.315 Delayed Quote.15.93%
NESTLÉ S.A. -2.59% 103.46 Delayed Quote.1.07%
share with twitter share with LinkedIn share with facebook
All news about AKORN, INC.
10/02AKORN INC : Bankruptcy or Receivership, Completion of Acquisition or Disposition..
AQ
10/02AKORN : Successfully Completes Sale to Lenders and Exits Chapter 11 Protection
PU
09/30AKORN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
09/11LVMH Blames Tiffany for Reversal -- WSJ
DJ
09/10LVMH Says Tiffany's Handling of Pandemic Invalidates Merger -- 3rd Update
DJ
09/10LVMH Says Tiffany's Handling of Pandemic Invalidates Merger -- 2nd Update
DJ
09/10LVMH Says Tiffany's Handling of Pandemic Invalidates Merger -- Update
DJ
09/09AKORN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
08/28AKORN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
08/14AKORN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
More news
Financials (USD)
Sales 2019 682 M - -
Net income 2019 -227 M - -
Net Debt 2019 723 M - -
P/E ratio 2019 -0,83x
Yield 2019 -
Capitalization 3,60 M 3,60 M -
EV / Sales 2018 1,47x
EV / Sales 2019 1,34x
Nbr of Employees 2 227
Free-Float 93,0%
Chart AKORN, INC.
Duration : Period :
Akorn, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Douglas S. Boothe President & Chief Executive Officer
Christopher C. Young Executive Vice President-Global Operations
Duane Andrew Portwood Chief Financial Officer & Executive Vice President
Mark M. Silverberg Executive VP-Operations & Technical Services
Bill Ostrowski Chief Information Office & SVP
Sector and Competitors
1st jan.Capitalization (M$)
AKORN, INC.-98.20%4
JOHNSON & JOHNSON-5.12%376 848
ROCHE HOLDING AG-4.22%283 828
PFIZER INC.-7.96%207 994
MERCK & CO., INC.-16.09%197 256
NOVARTIS AG-19.31%180 257